Systematic Review and Meta-analysis Cytopenias among patients with rheumatic diseases using methotrexate: a meta-analysis of randomized controlled clinical trials RHEUMATOLOGY

Objective. To conduct a systematic literature review and meta-analysis to estimate the incidence of anaemia, leucopoenia, neutropenia and thrombocytopenia associated with MTX plus folic acid among patients with rheumatic diseases. Methods. We searched MEDLINE, PubMed and EMBASE through August 2016 for all randomized controlled clinical trials with a MTX monotherapy arm. We excluded randomized controlled clinical trials for cancer and included only double-blind studies that reported on haematologic adverse events. Studies were excluded if patients did not receive folic acid or leucovorin supplementation. Full text articles were assessed by two independent reviewers. Incidence estimates were calculated using random-effects models. Results. Of 1601 studies identified, 30 (1.87%) were included, representing 3858 patients; all had RA. Seventeen trials reported on anaemia ( n =2032), 17 reported on leucopoenia ( n =2220), 16 reported on neutropenia ( n =2202) and 12 reported on thrombocytopenia ( n =1507). The incidence for any anaemia was 2.55% (95% CI 0.60 (cid:2) 5.47%), any leucopoenia 1.17% (95% CI 0.16 (cid:2) 2.80%), any neutropenia 1.77% (95% CI 0.33 (cid:2) 4.00%), and any thrombocytopenia 0.19% (95% CI 0.00 (cid:2) 0.86%). Four cases of severe anaemia were reported, as defined by authors, along with three cases of severe neutropenia. No cases of severe leucopoenia, severe thrombocytopenia or pancytopenia were reported. Conclusion. Cytopenias are an uncommon side effect of low-dose MTX with folic acid supplementation among RA patients. Further research is needed to reach a more precise estimate. . Incidence of anaemia was (cid:2) 2.55%, of leucopenia was (cid:2) 1.17%, of neutropenia was (cid:2) 1.77%, of thrombocyto- penia was (cid:2) 0.19%. . No cases of pancytopenia were reported across 30 trials representing 3858 individuals. . Folic acid supplementation and modern clinical guidelines may account for the infrequency of cytopenias.

[1]  G. Castañeda-Hernández,et al.  Efficacy of Leflunomide 100 mg Weekly Compared to Low Dose Methotrexate in Patients With Active Rheumatoid Arthritis. Double Blind, Randomized Clinical Trial , 2022 .

[2]  M. Santos,et al.  Portuguese recommendations for the use of methotrexate in rheumatic diseases - 2016 update. , 2017, Acta reumatologica portuguesa.

[3]  R. Gorodkin,et al.  BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs. , 2017, Rheumatology.

[4]  C. Bao,et al.  A randomized, controlled trial of efficacy and safety of Anbainuo, a bio-similar etanercept, for moderate to severe rheumatoid arthritis inadequately responding to methotrexate , 2016, Clinical Rheumatology.

[5]  K. Migita,et al.  Factors Associated with Myelosuppression Related to Low-Dose Methotrexate Therapy for Inflammatory Rheumatic Diseases , 2016, PloS one.

[6]  Naoki Ishiguro,et al.  The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression , 2015, Annals of the rheumatic diseases.

[7]  D. M. van der Heijde,et al.  Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study , 2015, Arthritis & rheumatology.

[8]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[9]  M. Genovese,et al.  Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study , 2014, Annals of the rheumatic diseases.

[10]  M. Genovese,et al.  Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial , 2013, Annals of the rheumatic diseases.

[11]  P. Brooks,et al.  Standardizing Assessment and Reporting of Adverse Effects in Rheumatology Clinical Trials II: the Rheumatology Common Toxicity Criteria v.2.0 , 2007, The Journal of Rheumatology.

[12]  Tamara Rader,et al.  Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis. , 2013, The Cochrane database of systematic reviews.

[13]  M. Genovese,et al.  A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate , 2013, Annals of the rheumatic diseases.

[14]  M. Genovese,et al.  Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial. , 2013, Arthritis and rheumatism.

[15]  B. Wyman,et al.  Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. , 2013, Arthritis and rheumatism.

[16]  Patrick Durez,et al.  Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study , 2012, Annals of the rheumatic diseases.

[17]  J. French,et al.  A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. , 2012, Arthritis and rheumatism.

[18]  C. Bao,et al.  A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis , 2012, Clinical Rheumatology.

[19]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[20]  Yoshiya Tanaka,et al.  Phase II study of tofacitinib (CP‐690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate , 2011, Arthritis care & research.

[21]  Ricardo Blanco,et al.  Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. , 2011, Arthritis and rheumatism.

[22]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[23]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[24]  D. M. van der Heijde,et al.  Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research , 2008, Annals of the rheumatic diseases.

[25]  V. Strand,et al.  Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Arthritis and rheumatism.

[26]  J. Smolen,et al.  Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial , 2008, The Lancet.

[27]  C. Bao,et al.  A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China , 2008, Rheumatology International.

[28]  R. Rau,et al.  Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate , 2005, Clinical Rheumatology.

[29]  R. Hughes,et al.  Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. , 2003, Rheumatology.

[30]  M. Weisman,et al.  Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.

[31]  Stanley B. Cohen,et al.  Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. , 2002, Arthritis and rheumatism.

[32]  B. Dijkmans,et al.  Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. , 2001, Arthritis and rheumatism.

[33]  Richard W. Martin,et al.  A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. , 2000, The New England journal of medicine.

[34]  P. Jones,et al.  Do patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term? , 2000, Rheumatology.

[35]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[36]  V. Strand,et al.  Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. , 1999, Archives of internal medicine.

[37]  D Kurosaka.  [Disease modifying anti-rheumatic drugs]. , 1999, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[38]  J. Kremer,et al.  A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. , 1999, The New England journal of medicine.

[39]  J. Knudsen,et al.  Prospectively measured red cell folate levels in methotrexate treated patients with rheumatoid arthritis: relation to withdrawal and side effects. , 1997, The Journal of rheumatology.

[40]  L. Espinoza,et al.  Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[41]  J. Esdaile,et al.  Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis. Results of a multicenter randomized, double-blind, placebo-controlled trial. , 1993, Arthritis and rheumatism.

[42]  M. Weinblatt,et al.  Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. , 1989, Arthritis and rheumatism.

[43]  G. Alarcón,et al.  Methotrexate in rheumatoid arthritis. Toxic effects as the major factor in limiting long-term treatment. , 1989, Arthritis and rheumatism.

[44]  A. Russell,et al.  Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression. , 1989, British journal of rheumatology.

[45]  M. Weinblatt.  Toxicity of low dose methotrexate in rheumatoid arthritis. , 1985, The Journal of rheumatology. Supplement.